Studies lasting several weeks to a few months have not identified concerning safety signals beyond the side effects already discussed
The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
Gastroenterology 149 , 14831489
Book a Consultation Today
Therefore, it's recommended to consult with a healthcare professional before starting any new treatment regimen
For the TG clearance tests, mice were fasted overnight (~15 h), then administered 20% intralipid (Sigma-Aldrich) via oral gavage (15 l g 1 body weight) at ZT2